Presurgery Bortezomib for Recurrent Malignant Gliomas Followed by Postop Bortezomib & Temozolomide
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the
growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving
bortezomib before surgery may make the tumor smaller and reduce the amount of normal tissue
that needs to be removed. Giving bortezomib together with temozolomide after surgery may kill
any tumor cells that remain after surgery.
This phase II trial is studying how well giving bortezomib before surgery followed by giving
bortezomib together with temozolomide after surgery works in treating patients with recurrent
malignant glioma.